CD19‑directed antibody‑drug conjugate that delivers a pyrrolobenzodiazepine (PBD) cytotoxic payload to B cells.
Humanized anti‑CD19 monoclonal antibody linked via a cleavable linker to a pyrrolobenzodiazepine (PBD) dimer. After binding CD19 on B cells and internalization, the linker is cleaved to release the PBD payload, which binds the DNA minor groove and forms interstrand cross‑links (N2 of guanine), blocking DNA replication and inducing cytotoxicity in CD19‑expressing tumor cells.
YES
DIRECT
ADC binds CD19, is internalized, and releases a PBD dimer that forms DNA interstrand cross-links (minor groove, N2 of guanine), blocking replication and killing the CD19+ cell.
A TROP2-targeting antibody–drug conjugate that binds TROP2 on tumor cells to deliver a cytotoxic payload.
Binds TROP2 on tumor cells, undergoes receptor-mediated internalization, and releases a cytotoxic payload intracellularly to kill TROP2-expressing cancer cells.
YES
DIRECT
The ADC binds TROP2, is internalized via receptor-mediated endocytosis, and releases a cytotoxic payload inside the cell that kills TROP2-expressing cells.
HER2-directed biologic intended to target HER2-expressing tumor cells; the exact modality is not specified in the record.
Bispecific anti-HER2 antibody-drug conjugate (anbenitamab linked to a topoisomerase-1 inhibitor). Binds two distinct HER2 epitopes on tumor cells, is internalized, and releases the topo-1 inhibitor payload, which stabilizes DNA–topoisomerase-1 cleavage complexes, prevents DNA re-ligation, induces DNA strand breaks, leading to cell-cycle arrest and apoptosis in HER2-expressing cells.
YES
DIRECT
ADC binds HER2 on tumor cells, is internalized, and releases a topoisomerase‑1 inhibitor that stabilizes topo‑1–DNA cleavage complexes, causing DNA strand breaks, cell‑cycle arrest, and apoptosis.
HER2-directed biologic intended to target HER2-expressing tumor cells; the exact modality is not specified in the record.
Bispecific anti-HER2 antibody-drug conjugate (anbenitamab linked to a topoisomerase-1 inhibitor). Binds two distinct HER2 epitopes on tumor cells, is internalized, and releases the topo-1 inhibitor payload, which stabilizes DNA–topoisomerase-1 cleavage complexes, prevents DNA re-ligation, induces DNA strand breaks, leading to cell-cycle arrest and apoptosis in HER2-expressing cells.
NO
INDIRECT
JSKN003 binds HER2 on tumor cells, is internalized, and releases a topoisomerase-1 inhibitor that poisons topo I to cause DNA damage and apoptosis. Topoisomerase I is the intracellular payload target, not the antigen determining which cells are killed.
Peptide cancer vaccine presenting the shared 36-amino-acid mutant calreticulin (CALR) C-terminal neoantigen to expand CALR-specific cytotoxic T cells targeting CALR-mutant malignant hematopoietic cells.
Synthetic peptide vaccine comprising the shared 36-amino-acid mutant calreticulin (CALR) C-terminal neoantigen. After uptake by antigen-presenting cells, the peptide is presented on MHC to prime and expand CALR-mutant–specific cytotoxic T cells (and helper T cells), leading to recognition and killing of CALR-mutant malignant hematopoietic cells; adjuvants (e.g., poly-ICLC) enhance dendritic cell activation and antigen presentation.
YES
INDIRECT
The peptide vaccine elicits CALR-mutant–specific CD8+ T cells; these CTLs recognize the mutant CALR peptide on MHC I of target cells and kill them via perforin/granzyme (and Fas–FasL) pathways.